Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 18,500 shares, a decrease of 43.6% from the March 31st total of 32,800 shares. Based on an average daily volume of 391,900 shares, the short-interest ratio is currently 0.0 days. Currently, 1.1% of the shares of the company are sold short.
Revelation Biosciences Stock Up 1.9 %
Shares of NASDAQ:REVB traded up $0.04 during trading on Friday, hitting $2.18. The stock had a trading volume of 45,620 shares, compared to its average volume of 315,485. Revelation Biosciences has a 12-month low of $1.78 and a 12-month high of $39.00. The stock has a market capitalization of $3.55 million, a price-to-earnings ratio of 0.07 and a beta of 0.11. The stock has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $10.90.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($8.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.94) by $2.61. As a group, sell-side analysts forecast that Revelation Biosciences will post -20.32 earnings per share for the current year.
Institutional Inflows and Outflows
About Revelation Biosciences
Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.
Read More
- Five stocks we like better than Revelation Biosciences
- ESG Stocks, What Investors Should Know
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Invest in Insurance Companies: A GuideĀ
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Insider Trading – What You Need to Know
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.